From: Multiple Sclerosis News Today

By: Ana Pena, PHD.

Ocrevus Use Rises Among New Starters with RRMS, Loses Ground to Other Therapies in PPMS

First-line use of Genentech’s Ocrevus (ocrelizumab) for patients with multiple sclerosis (MS) has remained stable through 2019 compared to 2018, according to the latest Spherix Global Insights’ report…(read more).